This week

This weekly brief summarizes key regulatory, clinical, and guideline developments in the fields of psoriasis and atopic dermatitis (AD) for the period of April 1, 2026, to April 17, 2026.

Approvals

Anzupgo (delgocitinib) cream — FDA sNDA Acceptance · April 15, 2026 Source: leo-pharma.com/media-center/news/2026-acceptance-of-anzupgo-snda Why it matters: If approved, this topical pan-JAK inhibitor would be the first indicated treatment specifically for pediatric patients (ages 12–17) with moderate-to-severe chronic hand eczema (CHE).

Icotyde (icotrokinra) — Commercial Launch/Update · April 7, 2026 Source: fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 Why it matters: Following its mid-March approval, new 1-year data confirmed its position as the first targeted oral peptide for IL-23 receptor antagonism, offering biologic-like efficacy in a daily pill for plaque psoriasis.

Trial readouts

Zasocitinib — Phase 3 LATITUDE results (Full Data) · April 7, 2026 Source: clinicaltrials.gov/study/NCT06671483 / hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Demonstrated superiority over placebo and apremilast in moderate-to-severe psoriasis, with nearly 30% of patients achieving PASI 100 at week 16, reinforcing the strength of the next-gen TYK2 inhibitor pipeline.

Rademikibart — Phase 3 RADIANT-AD 52-week data · April 7, 2026 Source: hcplive.com/view/6-dermatology-headlines-you-missed-march-2026 Why it matters: Long-term data showed sustained near-maximal skin clearance and pruritus control through one year, establishing it as a highly durable IL-4Rα antagonist competitor.

Guideline / safety updates

AAD 2026 Guidelines: Management of Atopic Dermatitis in Pediatric Patients — Publication · April 7, 2026 Source: jaad.org/article/S0190-9622(26)00113-X/fulltext Why it matters: The first pediatric-specific AD guidelines from the AAD, granting "Strong" evidence-based recommendations for aryl hydrocarbon receptor (AhR) agonists like tapinarof in children as young as 2 years old.

International Eczema Council (IEC) Consensus Statement — JAMA Dermatology · April 15, 2026 Source: jamanetwork.com/journals/jamadermatology/fullarticle/2816625 Why it matters: Standardizes the definitions for "Low Disease Activity" and "Remission" in AD, providing essential benchmarks for clinical trial design and "treat-to-target" strategies in routine practice.